Clinical Research Directory
Browse clinical research sites, groups, and studies.
Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention
Sponsor: Stanford University
Summary
This trial is designed to determine whether modifying the dose of isoniazid for individuals according to their n-acetyltransferase 2 (NAT2) genotype could increase the probability of achieving equivalence of area-under-the-curve.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
78
Start Date
2023-03-23
Completion Date
2025-06-25
Last Updated
2026-06-15
Healthy Volunteers
No
Interventions
Low-dose isoniazid
Pharmacogenomic-modified dose of isoniazid - 5 mg/kg oral tablet (maximum 300 mg)
Standard dose of isoniazid
15 mg/kg oral tablet (up to 900 mg)
High-dose isoniazid
Pharmacogenomic-modified dose of isoniazid - 25 mg/kg oral tablet (maximum 1500 mg)
Locations (1)
Federal University of Mato Grosso do Sul
Campo Grande, Mato Grosso do Sul, Brazil